Clinical Edge Journal Scan

Does high consumption of nuts and legumes protect against CRC?


 

Key clinical point: Individuals with the highest vs. lowest intake of nuts and legumes had a 16% and 10% lower risk for colorectal cancer (CRC), respectively.

Major finding: The pooled relative risk (RR) for CRC among individuals with the highest vs. lowest consumption of nuts and legumes was 0.84 (95% CI 0.71-0.99) and 0.90 (95% CI 0.83-0.98), respectively. A once-daily consumption of 28 g nuts and 100 g legumes was associated with a 33% (RR 0.67; 95% CI 0.45-0.98) and 21% (RR 0.79; 95% CI 0.64-0.97) lower risk for CRC, respectively.

Study details: Findings are from a meta-analysis of 13 and 29 studies that evaluated the association of the consumption of nuts and legumes with CRC risk, respectively.

Disclosures: The study was supported by the National Research Foundation of Korea, Ministry of Science, ICT, and Future Planning. The authors declared no conflicts of interest.

Source: Jin S, Je Y. Nuts and legumes consumption and risk of colorectal cancer: A systematic review and meta-analysis. Eur J Epidemiol. 2022 (May 27). Doi: 10.1007/s10654-022-00881-6

Recommended Reading

AGA issues position statements on reducing CRC burden
MDedge Hematology and Oncology
AI-based CADe outperforms high-definition white light in colonoscopy
MDedge Hematology and Oncology
New treatment reduces risk of anal cancer in people with HIV
MDedge Hematology and Oncology
Intensified chemotherapy confers no additional benefits with panitumumab in RAS and BRAF wt mCRC
MDedge Hematology and Oncology
Atezolizumab added to FOLFOXIRI + bevacizumab seems safe and beneficial in previously untreated mCRC
MDedge Hematology and Oncology
Therapy trends in patients with mCRC after the second disease progression
MDedge Hematology and Oncology
Is iatrogenic tumor seeding a risk factor for metachronous CRC? Evidence suggests otherwise
MDedge Hematology and Oncology
Heavy drinking associated with increased risk for EOCRC irrespective of genetic risk
MDedge Hematology and Oncology
Refractory metastatic CRC: Raltitrexed plus S-1 betters regorafenib in prolonging survival
MDedge Hematology and Oncology
CRC with synchronous liver metastases: Outcomes of simultaneous laparoscopic vs. hybrid and open resection
MDedge Hematology and Oncology